Using AI To Advance Imaging Operations & Analysis in Phase III Clinical Trials for Alzheimer’s
Who Should Attend?
This webinar is suitable job titles in the following departments:
- CMO, CSO, CIO
- Heads of: R&D, Clinical Research, Clinical Development, Clinical Operations
- TA Head/Lead
- Clinical Lead
- Clinical Scientists
- Imaging Scientist
- Biomarkers Scientists
- Study/Project Manager
- Protocol Manager
- Study Startup
What You Will Learn
- An overview of imaging biomarkers in Alzheimer’s clinical trials
- Addressing the challenges in imaging operations for Phase III Alzheimer’s clinical trials
- Streamlining imaging operations: from site qualification to data management
- Harnessing LEAP AI technology to advance segmentation and volumetric analysis
Roger Bullock, Chief Medical Officer, Oryzon
Dr. Bullock is considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.
Shona Clegg, Associate Director Client Services, IXICO
Shona joined IXICO in 2016, and has managed clinical trial projects for clients in a variety of phases and therapeutic areas, including Alzheimer’s, Progressive Supranuclear Palsy and Parkinson’s disease, across a wide range of protocols encompassing MRI, dMRI/ DTI, functional MRI, and PET imaging. With her extensive operational experience of on-time and on-budget project delivery, Shona’s current role includes quality and service management to help clients achieve their imaging objectives with utmost quality performance.
Richard Joules, Imaging Science Manager, IXICO
Richard has over seven years’ experience working in imaging both in an academic and commercial setting. Holds a PhD from Kings College London in neuroimaging, assessing the application of machine learning to pharmacological resting state fMRI. Richard has worked in a range of therapeutic areas, such Alzheimer’s Disease, Huntington’s Disease and Progressive Supranuclear Palsy, to develop methods for biomarker detection and disease monitoring. As the current imaging science manager at IXICO, he is responsible for the deployment and monitoring of analysis solutions in clinical trials.